Floatz logo

Interleukin-12

Neuroectodermal Tumors

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Neuroectodermal Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
DNAtrix, Inc.
Phase 2B
TASADENOTUREV
DNAtrix, Inc.
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
axp107-11
University of Virginia
Phase 2CCC
Belzutifan
José Claudio Casali da Rocha
Phase 2CCC

View all 21 →

Same molecule, other indications

Interleukin-12 is also rated in:

immune system disorderDormant
CCC
Indicative ·
48 / 100
View asset →
neuroepithelial neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
nervous system neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →